Inherited cardiomyopathies

BMJ (Online)

Volumn 343, Issue 7833, 2011, Pages 1106-1110

  Raju, Hariharan ^a   Alberg, Corinna ^b   Sagoo, Gurdeep S ^b   Burton, Hilary ^b   Behr, Elijah R ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b PHG FOUNDATION   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; SOTALOL; SPIRONOLACTONE; VERAPAMIL;

CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; DISEASE COURSE; DISEASE SEVERITY; ELECTROCARDIOGRAM; FAMILY HISTORY; GENE MUTATION; GENERAL PRACTITIONER; GENETIC RISK; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART OUTFLOW TRACT OBSTRUCTION; HEART SURGERY; HUMAN; HUMAN GENETICS; HYPERTROPHIC CARDIOMYOPATHY; INHERITANCE; MEDICAL SPECIALIST; PATIENT ATTITUDE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SUDDEN DEATH; SYMPTOM;

ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOMYOPATHIES; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; EVIDENCE-BASED MEDICINE; FAMILY PRACTICE; GREAT BRITAIN; HUMANS; MAGNETIC RESONANCE IMAGING; PHYSICIAN'S ROLE; PHYSICIANS, FAMILY; PREVALENCE; RISK FACTORS;

EID: 82255164740     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d6966     Document Type: Review

References (30)

1. Burton H, Alberg C, Stewart A. Heart to heart: inherited cardiovascular conditions services - a needs assessment and service review. PHG Foundation, 2009. www. phgfoundation.org/file/4668/.
2. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:1533-41.
3. Millat G, Bouvagnet P, Chevalier P, Dauphin C, Jouk PS, Da Costa A, et al. Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. Eur J Med Genet 2010;53:261-7.
4. Mahon NG, Murphy RT, MacRae CA, Caforio ALP, Elliott PM, McKenna WJ. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. Ann Intern Med 2005;143:108-15.
5. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746-837.
6. Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-713. (Pubitemid 37383745)
7. Hendrix A, Borleffs CJW, Vink A, Doevendans PA, Wilde AA, van Langen IM, et al. Cardiogenetic screening of first-degree relatives after sudden cardiac death in the young: a population-based approach. Europace 2011;13:716-22.
8. Bos JM, Ommen SR, Ackerman MJ. Genetics of hypertrophic cardiomyopathy: one, two, or more diseases? Curr Opin Cardiol 2007;22:193-9. (Pubitemid 46581194)
9. Hershberger RE, Siegfried JD. Update 2011: clinical and genetic issues in familial dilated cardiomyopathy. J Am Coll Cardiol 2011;57:1641-9.
10. Vetter VL, Dugan N, Guo R, Mercer-Rosa L, Gleason M, Cohen M, et al. A pilot study of the feasibility of heart screening for sudden cardiac arrest in healthy children. Am Heart J 2011;161:1000-6.e3.
11. Maron BJ. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Circ J 2010;74:2271-82.
12. Pinamonti B, Dragos AM, Pyxaras SA, Merlo M, Pivetta A, Barbati G, et al. Prognostic predictors in arrhythmogenic right ventricular cardiomyopathy: results from a 10-year registry. Eur Heart J 2011;32:1105-13.
13. De Noronha SV, Sharma S, Papadakis M, Desai S, Whyte G, Sheppard MN. Aetiology of sudden cardiac death in athletes in the United Kingdom: a pathological study. Heart 2009;95:1409-14.
14. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation 1982;65:1388-94. (Pubitemid 12123632)
15. Bowker TJ, Wood DA, Davies MJ. Sudden unexpected cardiac death: methods and results of a national pilot survey. Int J Cardiol 1995;52:241-50.
16. Papadakis M, Sharma S, Cox S, Sheppard MN, Panoulas VF, Behr ER. The magnitude of sudden cardiac death in the young: a death certificate-based review in England and Wales. Europace 2009;11:1353-8.
17. Savage DD, Seides SF, Clark CE, Henry WL, Maron BJ, Robinson FC, et al. Electrocardiographic findings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 1978;58:402-8. (Pubitemid 9006966)
18. Marcus GM, Glidden DV, Polonsky B, Zareba W, Smith LM, Cannom DS, et al. Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC registry. J Am Coll Cardiol 2009;54:609-15.
19. Garratt CJ, Elliott P, Behr E, Camm AJ, Cowan C, Cruickshank S, et al. Heart Rhythm UK position statement on clinical indications for implantable cardioverter defibrillators in adult patients with familial sudden cardiac death syndromes. Europace 2010;12:1156-75.
20. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
21. McLeod CJ, Shen WK, Rea RF, Friedman PA, Hayes DL, Wokhlu A, et al. Differential outcome of cardiac resynchronization therapy in ischemic cardiomyopathy and idiopathic dilated cardiomyopathy. Heart Rhythm 2011;8:377-82.
22. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;46:470-6. (Pubitemid 41040288)
23. Wichter T, Paul TM, Eckardt L, Gerdes P, Kirchhof P, Böcker D, et al. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz 2005;30:91-101. (Pubitemid 40576527)
24. Kozeluhova M, Peichl P, Cihak R, Wichterle D, Vancura V, Bytesnik J, et al. Catheter ablation of electrical storm in patients with structural heart disease. Europace 2011;13:109-13.
25. Maron MS, Kalsmith BM, Udelson JE, Li W, DeNofrio D. Survival after cardiac transplantation in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010;3:574-9.
26. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301-7. (Pubitemid 34084637)
27. Garratt CJ, Elliott P, Behr E, Blair E, Connelly D, Cowan C, et al. Clinical indications for genetic testing in familial sudden cardiac death syndromes: an HRUK position statement. Heart 2008;94:502-7. (Pubitemid 351441410)
28. Xu T, Yang Z, Vatta M, Rampazzo A, Beffagna G, Pilichou K, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2010;55:587-97.
29. Wordsworth S, Leal J, Blair E, Legood R, Thomson K, Seller A, et al. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J 2010;31:926-35.
30. Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term outcome and risk stratification in dilated cardiolaminopathies. J Am Coll Cardiol 2008;52:1250-60.